See more : Cinemark Holdings, Inc. (CNK) Income Statement Analysis – Financial Results
Complete financial analysis of Verrica Pharmaceuticals Inc. (VRCA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Verrica Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- RWE Aktiengesellschaft (RWNFF) Income Statement Analysis – Financial Results
- BriaCell Therapeutics Corp. (BCTXW) Income Statement Analysis – Financial Results
- The Goodyear Tire & Rubber Company (0QLL.L) Income Statement Analysis – Financial Results
- MetalsTech Limited (MTC.AX) Income Statement Analysis – Financial Results
- PT Gudang Garam Tbk (GGNPF) Income Statement Analysis – Financial Results
Verrica Pharmaceuticals Inc. (VRCA)
About Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.12M | 9.03M | 12.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 746.00K | 725.00K | 472.00K | 229.00K | 257.20K | 20.29K | 0.00 | 0.00 |
| Gross Profit | 4.38M | 8.31M | 11.53M | -229.00K | -257.20K | -20.29K | 0.00 | 0.00 |
| Gross Profit Ratio | 85.44% | 91.97% | 96.07% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 20.30M | 12.20M | 15.93M | 15.67M | 15.44M | 12.83M | 3.73M | 1.71M |
| General & Administrative | 0.00 | 17.41M | 26.98M | 24.51M | 14.64M | 9.05M | 727.00K | 204.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 47.31M | 17.41M | 26.98M | 24.51M | 14.64M | 9.05M | 727.00K | 204.00K |
| Other Expenses | 2.54M | -58.00K | 0.00 | -1.00K | 1.87M | -1.00K | 0.00 | 0.00 |
| Operating Expenses | 70.14M | 29.60M | 42.91M | 40.18M | 30.08M | 21.88M | 4.46M | 1.91M |
| Cost & Expenses | 70.88M | 30.33M | 42.91M | 40.18M | 30.08M | 21.88M | 4.46M | 1.91M |
| Interest Income | 2.74M | 476.00K | 123.00K | 521.00K | 1.88M | 1.23M | 0.00 | 0.00 |
| Interest Expense | 3.96M | 2.17M | 4.30M | 3.03M | 0.00 | 0.00 | 2.00K | 0.00 |
| Depreciation & Amortization | 836.00K | 718.00K | 472.00K | 229.00K | 257.20K | 20.29K | 4.46M | 1.91M |
| EBITDA | -62.20M | -21.60M | -30.31M | -39.43M | -30.08M | -20.63M | -4.46M | -1.91M |
| EBITDA Ratio | -1,213.84% | -231.16% | -256.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -65.76M | -21.30M | -30.91M | -40.18M | -30.08M | -21.88M | -4.46M | -1.91M |
| Operating Income Ratio | -1,283.35% | -235.78% | -257.57% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.24M | -3.19M | -4.17M | -2.51M | 1.87M | 1.23M | -2.00K | 0.00 |
| Income Before Tax | -67.00M | -24.49M | -35.08M | -42.69M | -28.21M | -20.65M | -4.46M | -1.91M |
| Income Before Tax Ratio | -1,307.47% | -271.11% | -292.33% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 3.19M | 3.82M | 2.80M | -257.00K | 1.23M | -4.46M | -1.91M |
| Net Income | -67.00M | -27.68M | -38.90M | -45.50M | -27.95M | -20.65M | -4.46M | -1.91M |
| Net Income Ratio | -1,307.47% | -306.44% | -324.19% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.48 | -0.81 | -1.44 | -1.82 | -1.12 | -1.41 | -0.22 | -0.10 |
| EPS Diluted | -1.48 | -0.81 | -1.44 | -1.82 | -1.12 | -1.41 | -0.22 | -0.10 |
| Weighted Avg Shares Out | 45.34M | 34.16M | 27.04M | 25.00M | 24.90M | 14.66M | 19.95M | 19.95M |
| Weighted Avg Shares Out (Dil) | 45.34M | 34.16M | 27.04M | 25.00M | 24.90M | 14.66M | 19.95M | 19.95M |
Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Tops Revenue Estimates
Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results
Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma
Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024
7 Short-Squeeze Stocks That Could Beat Down the Bears
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
Verrica Pharmaceuticals Announces Amendment to Company's Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
Verrica Pharmaceuticals, Inc. (VRCA) Q1 2024 Earnings Call Transcript
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates
Source: https://incomestatements.info
Category: Stock Reports